The economic value of a quadrivalent versus trivalent influenza vaccine

► We model the economic value of a QIV compared to the TIV for ten influenza seasons. ► QIV provided cost savings during the decade if used instead of the TIV. ► A higher costing (up to $120) vaccine would still be beneficial in some seasons. ► Adding an additional B strain could reap substantial savings.